Credit Suisse Reports Ariad's Iclusig is 'Essential Drug'

In a report published Friday, Credit Suisse analyst Jason Kantor maintained a Neutral rating on Ariad Pharmaceuticals ARIA and raised the price target from $5.00 to $8.00 on higher Iclusig estimates and possible acquisition. Kantor noted that a survey from 50 doctors suggests that Ariad's Iclusig remains the “essential drug” for chronic myeloid leukemia patients with T3151 or other mutations. The analyst commented that doctors have a heightened awareness of safety concerns. Credit Suisse added that 38% of doctors sampled report observing at least one adverse event listed in warnings in Iclusig prescribing information. Ariad Pharmaceuticals closed at $7.17 on Thursday. Shares were up 5.6% in pre-market trading and have traded as high as $8.29, up 15.62% on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsCredit SuisseJason Kantor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!